Author Question: A client is to receive darbepoetin alfa (Aranesp) adjunctive medication during chemotherapy. The ... (Read 107 times)

natalie2426

  • Hero Member
  • *****
  • Posts: 524
A client is to receive darbepoetin alfa (Aranesp) adjunctive medication during chemotherapy. The client says, Not another drug. Why do I need this one? How should the nurse respond?
 
  1. I know you are tired of drugs, but this is just one more.
  2. This drug will help you grow red blood cells.
  3. This drug will help keep you from getting infections.
  4. This is an erythropoiesis-stimulating factor.
  5. This drug will help you get more oxygen around to your tissues so you feel better.

Question 2

A client has been treated with an erythropoiesis-stimulating factor. Which client assessment would the nurse interpret as indicating the goal of this treatment has been reached?
 
  1. The client's hemoglobin values have risen.
  2. The client reports less shortness of breath on exertion.
  3. The client has not had an episode of epistaxis in over three weeks.
  4. The client reports enjoying a walk with family for the first time in months.
  5. The client has not had a fever since treatment began.



pikon

  • Sr. Member
  • ****
  • Posts: 361
Answer to Question 1

Correct Answer: 2,5
Rationale 1: This response does not answer the client's question.
Rationale 2: Darbepoetin alfa (Aranesp) is an erythropoiesis-stimulating factor.
Rationale 3: Darbepoetin alfa (Aranesp) does not increase immunity.
Rationale 4: The nurse should explain the medication in terms the client can understand.
Rationale 5: Darbepoetin alfa (Aranesp) stimulates production of red blood cells which carry oxygen. Getting additional oxygen to the tissues helps the client feel better.

Answer to Question 2

Correct Answer: 1,2,4
Rationale 1: The purpose of this therapy is to increase red blood cells which would increase hemoglobin.
Rationale 2: Since the client has more RBCs, more oxygen can be carried to tissues.
Rationale 3: This drug supports RBC production, not platelet production.
Rationale 4: Increase in activity level indicates treatment success.
Rationale 5: This treatment supports red blood cell production, not white blood cell production.



Related Topics

Need homework help now?

Ask unlimited questions for free

Ask a Question


 

Did you know?

Chronic necrotizing aspergillosis has a slowly progressive process that, unlike invasive aspergillosis, does not spread to other organ systems or the blood vessels. It most often affects middle-aged and elderly individuals, spreading to surrounding tissue in the lungs. The disease often does not respond to conventionally successful treatments, and requires individualized therapies in order to keep it from becoming life-threatening.

Did you know?

Bisphosphonates were first developed in the nineteenth century. They were first investigated for use in disorders of bone metabolism in the 1960s. They are now used clinically for the treatment of osteoporosis, Paget's disease, bone metastasis, multiple myeloma, and other conditions that feature bone fragility.

Did you know?

It is believed that humans initially contracted crabs from gorillas about 3 million years ago from either sleeping in gorilla nests or eating the apes.

Did you know?

After 5 years of being diagnosed with rheumatoid arthritis, one every three patients will no longer be able to work.

Did you know?

Asthma is the most common chronic childhood disease in the world. Most children who develop asthma have symptoms before they are 5 years old.

For a complete list of videos, visit our video library